Cellular and T cell engager Immunotherapy
Longer-Term Follow-Up of Patients Receiving Prophylactic Tocilizumab for Cytokine Release Syndrome in the Phase 1/2 MajesTEC-1 Study of Teclistamab in Relapsed/Refractory Multiple Myeloma
Laura Rosinol, MD, PhD (she/her/hers)
Amyloidosis and Myeloma Unit, Department of Hematology
Hospital Clínic de Barcelona, IDIBAPS, Barcelona, Spain
Barcelona, Catalonia, Spain